• linkedin
  • Increase Font
  • Sharebar

    Anti-androgen’s benefit in chemo-naïve men tops prostate cancer news

    The androgen-receptor blocker enzalutamide (XTANDI) increases survival by 29% in men with metastatic castration-resistant prostate cancer (mCRPC) and delays progression of the disease by 81%, according to new phase III study results in men who had not previously received chemotherapy.

    The impressive enzalutamide findings arguably made the biggest news at the recently concluded Genitourinary Cancers Symposium in San Francisco. But there were other advances reported in advanced prostate cancer treatment, including positive findings on combination radiotherapy/anti-androgen therapy in men with locally advanced disease and evidence that prostate cancer immunotherapy results in humoral antigen spread.

    Preliminary results from the phase III PREVAIL study of enzalutamide were released in October 2013 after the Independent Data Monitoring Committee recommended that the study be stopped early. The data were presented in full for the first time at the Genitourinary Cancers Symposium.

    “Enzalutamide is likely to become an important new treatment option that has a significant impact on the progression of prostate cancer,” said lead author Tomasz Beer, MD, of Oregon Health and Science University, Portland. “If approved for this indication, it will become an important standard option for use before chemotherapy in patients with asymptomatic or minimally symptomatic advanced prostate cancer.”

    In the double-blind, placebo-controlled study, 1,717 chemotherapy-naïve men with mCRPC were randomized to receive enzalutamide or placebo plus standard hormone therapy. Participants had previously received treatment for the primary tumor, such as surgery or radiation therapy, as well as hormone therapy with an LHRH agonist or a first-generation anti-androgen.

    Results showed that enzalutamide treatment significantly reduced the risk of death by 29% (HR: 0.71, p<.0001), compared with placebo and significantly reduced the risk of radiographic progression or death by 81% versus placebo (HR: 0.19, p<.0001). In addition, on average, patients receiving enzalutamide needed chemotherapy 17 months later than those in the placebo arm.

    Common side effects that were more common in the enzalutamide-treated men included fatigue, back pain, constipation, and arthralgia. Hypertension was observed in 13.4% of enzalutamide versus 4.1% of placebo-treated patients. Dr. Beer and colleagues reported zero seizures in the enzalutamide-treated group and one in the placebo group prior to the data cutoff date. One seizure was reported in the enzalutamide group after the data cutoff date.

    Dr. Beer has received research funding from Astellas Pharma, Cougar Biotechnology, Janssen Biotech, and Medivation. Several study co-authors report relationships with Astellas and Medivation.

    Continue to next page for additional coverage of advanced prostate cancer treatment.


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available